Compare FuelCell Energy Inc (FCEL) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Eli Lilly And Co — how do they compare? FuelCell Energy Inc trades at $17.82 (market cap $1.62B), while Eli Lilly And Co trades at $1,182.52 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 635.8× FuelCell Energy Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| FCEL | LLY | |
|---|---|---|
Market Cap | $1.62B | $1.03T |
Sector | Industrials | Health |
52-Week High | $36.01 | $1.24K |
52-Week Low | $3.92 | $625.65 |
Enterprise Value | $1.47B | $1.07T |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $21.35, up 11.9% in the last 24 hours, reflecting high volatility amid recent news. The stock shows a neutral technical signal with bearish moving averages, while fundamentals reveal persistent losses with a net income margin of -132.41% in 2025 despite revenue growth to $158.16M. Recent developments include a strategic partnership with Siemens to scale clean power solutions and a $225M stock offering that caused temporary dilution concerns.
The outlook is mixed: analyst consensus is balanced with a $20.75 price target, but continued cash burn and high valuation multiples pose risks. Opportunities lie in AI-driven data center demand, though profitability remains a key challenge for sustainable upside.
LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.
Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
